MedPath

Study of Difluprednate in the Treatment of Uveitis

Phase 3
Completed
Conditions
Uveitis
Registration Number
NCT00501579
Lead Sponsor
Sirion Therapeutics, Inc.
Brief Summary

The purpose of this study is to determine the safety and efficacy of difluprednate compared with prednisolone acetate in the treatment of endogenous anterior uveitis.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Diagnosis of endogenous anterior uveitis in at least 1 eye
Exclusion Criteria
  • Presence of intermediate uveitis, posterior uveitis or panuveitis
  • Corneal abrasion
  • Any confirmed or suspected active viral, bacterial, or fungal keratoconjunctival disease
  • Allergy to similar drugs, such as other corticosteroids

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

John-Kenyon American Eye Institute

🇺🇸

New Albany, Indiana, United States

© Copyright 2025. All Rights Reserved by MedPath